Charles River Laboratories International logo
Charles River Laboratories International CRL
$ 269.48 0.06%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Charles River Laboratories International Financial Statements 2025-2007 | CRL

Annual Financial Statements Charles River Laboratories International

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Market Cap

7.69 B 8.54 B 12.5 B 11 B 14.6 B 14.2 B 7.68 B 5.81 B 5.22 B 3.68 B 3.61 B 3.36 B 2.77 B 2.05 B 1.7 B 2.09 B 2.05 B - -

Shares

49.6 M 51.4 M 51.2 M 50.8 M 50.3 M 49.6 M 49.7 M 49 M 48.6 M 47 M 47.6 M 47.6 M 48.5 M 48.4 M 50.8 M 62.6 M 65.4 M - -

Historical Prices

155 166 244 217 291 286 156 142 107 87 73.4 76.7 59.4 40.7 35.1 33.4 31.4 64.6 53.5

Net Income

-144 M 22.2 M 475 M 486 M 391 M 364 M 252 M 226 M 123 M 155 M 149 M 127 M 103 M 97.3 M 110 M -337 M 114 M -525 M -

Revenue

4.02 B 4.05 B 4.13 B 3.98 B 3.54 B 2.92 B 2.62 B 2.27 B 1.86 B 1.68 B 1.36 B 1.3 B 1.17 B 1.13 B 1.14 B - - - -

Gross Profit

- - - - - - 958 M 840 M 701 M 647 M 532 M 476 M 401 M 397 M 402 M - - - -

Operating Income

25.2 M 227 M 617 M 651 M 590 M 433 M 351 M 331 M 288 M 238 M 206 M 178 M 151 M 166 M 174 M -299 M 170 M -452 M -

Interest Expense

-22.6 M -16.5 M 137 M 59.3 M 73.9 M 86.4 M 60.9 M 63.8 M 29.8 M 27.7 M 15.1 M 12 M 21 M 33.3 M 42.6 M 35.3 M 21.7 M 22.3 M -

EBITDA

428 M 589 M 931 M 955 M 855 M 668 M 549 M 493 M 419 M 279 M 301 M 274 M 248 M 247 M 204 M -205 M 260 M -365 M -

Operating Expenses

- - - - - - 607 M 509 M 413 M 409 M 325 M 298 M 249 M 231 M 220 M - - - -

General and Administrative Expenses

743 M 751 M 748 M 665 M 620 M 529 M 486 M 420 M 365 M 368 M 283 M 264 M 224 M 207 M 199 M 232 M 228 M 224 M -

All numbers in USD currency

Quarterly Income Statement Charles River Laboratories International

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3 2010-Q2

Shares

48 B 49 M 49.2 M 49.1 M 50.7 M 51.1 M 51.4 M 51.6 M 51.4 M 51.3 M 51.3 M 51.2 M 51.1 M 50.9 M 50.9 M 50.8 M 50.6 M 50.5 M 50.4 M 50.3 M 50 M 49.8 M 49.7 M 49.6 M 49.2 M 48.9 M 48.8 M 48.8 M 48.5 M 48.2 M 48.3 M 48.2 M 47.8 M 47.4 M 47.5 M 47.6 M 47.5 M 47.4 M 47.2 M 47.1 M 46.6 M 46.7 M 46.3 M 46.7 M 46.8 M 47.3 M 46 M 46.9 M 47.1 M 47.6 M 47.9 M 48.3 M 47.7 M 48.9 B 47.6 M 48 M 48.3 M 48.9 M 50.1 M 51 M 53.9 M 57.7 M 66.3 M

Net Income

-1.48 M -14.8 M 54.4 M 52.3 M 25.5 M - 69.7 M 94.1 M 73 M - 87.4 M 97 M 103 M - 96.5 M 109 M 93 M - 103 M 88.4 M 61.5 M 143 M 103 M 67.4 M 50.8 M 80.3 M 72.8 M 43.7 M 55.1 M 59.7 M 60.4 M 53.7 M 52.6 M -29.8 M 52.5 M 54 M 46.8 M 44.7 M 37.7 M 35.2 M 37.1 M 31.9 M 37.4 M 48.5 M 31.5 M 27.2 M 32.4 M 35.8 M 32.4 M 19.1 M 31.2 M 27.7 M 25.8 M - 22.2 M 30.6 M 26.5 M - 18.9 M 32.3 M 31.3 M -24.9 M 14.5 M

Revenue

1 B 996 M 1 B 1.03 B 984 M - 1.01 B 1.03 B 1.01 B - 1.03 B 1.06 B 1.03 B - 989 M 973 M 914 M - 896 M 915 M 825 M 791 M 743 M 683 M 707 M 691 M 668 M 658 M 605 M 602 M 585 M 585 M 494 M 478 M 464 M 469 M 446 M 467 M 426 M 434 M 355 M 354 M 349 M 340 M 320 M 330 M 328 M 341 M 299 M 289 M 292 M 293 M 291 M - 279 M 285 M 286 M - 278 M 288 M 286 M - -

Cost of Revenue

- - - - - - 661 M 672 M - - 665 M 661 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - 300 M 289 M 232 M 252 M 262 M 246 M 238 M 212 M 226 M 216 M 216 M 181 M 167 M 177 M 185 M 171 M 180 M 156 M 170 M 141 M 141 M 138 M 133 M 120 M 120 M 118 M 126 M 109 M 88.2 M 99.9 M 103 M 104 M - - - - - - - - - -

Operating Income

120 M 120 M 134 M 100 M 74.7 M - 117 M 152 M 126 M - 152 M 165 M 168 M - 151 M 187 M 149 M - 156 M 138 M 124 M 129 M 133 M 76.8 M 94.3 M 109 M 92.8 M 79.8 M 69.8 M 102 M 84.4 M 76.7 M 67.8 M 62.8 M 74.1 M 81.7 M 69.7 M 69.1 M 58.8 M 58.1 M 51.5 M 52.3 M 55.4 M 55.7 M 43 M 40.8 M 46.2 M 51 M 39.7 M 24.6 M 40.8 M 43.2 M 42.8 M - 37.7 M 49.3 M 43.7 M - 37.1 M 53.3 M 42.3 M 5.11 M 28.2 M

Interest Expense

-37.4 M -124 M -22.6 M 154 K -12.2 M - 2.59 M -2.24 M 5.83 M - -6.26 M -2.66 M 34.4 M - 11.4 M 3.7 M 9.43 M - 16.5 M 16.2 M 29.7 M - 18.9 M 19.4 M 15.1 M - 5.7 M 20.8 M 9.99 M - 17.2 M 18.6 M 11.2 M - 7.67 M 7.4 M 6.98 M - 7.08 M 8.91 M 4.21 M - 3.85 M 4.38 M 3.02 M - 3 M 3.37 M 2.8 M - 2.32 M 7.54 M 8.28 M - 8.52 M 8.08 M 8.44 M - 11.9 M 10.7 M 10 M 12.6 M 7.1 M

EBITDA

187 M 187 M 219 M 220 M 195 M - 206 M 238 M 211 M - 230 M 243 M 245 M - 226 M 264 M 224 M - 224 M 206 M 185 M 129 M 192 M 134 M 152 M 109 M 145 M 129 M 115 M 102 M 128 M 120 M 101 M 62.8 M 108 M 113 M 102 M 69.1 M 92.9 M 90.4 M 76.1 M 52.3 M 79.3 M 78.9 M 65.4 M 40.8 M 72.2 M 75.3 M 59.8 M 24.6 M 108 M 83.6 M 62.8 M - 98.3 M 89.3 M 63.7 M - 101 M 96.4 M 63.5 M 77.1 M 76.1 M

General and Administrative Expenses

229 M 159 M 178 M 192 M 178 M - 199 M 170 M 186 M - 176 M 200 M 175 M - 184 M 132 M 150 M - 149 M 172 M 156 M - 128 M 128 M 130 M - 130 M 136 M 123 M - 113 M 121 M 103 M - 92.4 M 93.8 M 90.9 M - 85.6 M 100 M 82.9 M - 76.2 M 71.3 M 71.4 M - 64.5 M 67.8 M 64.8 M - 54.9 M 54.9 M 57.2 M - 51 M 49.9 M 56 M - 50.3 M 47.2 M 55 M 49.2 M 66.1 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Charles River Laboratories International CRL
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Charles River Laboratories International plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.81 1.63 % $ 91.2 K usaUSA
Biodesix Biodesix
BDSX
$ 27.49 1.95 % $ 208 M usaUSA
Biomerica Biomerica
BMRA
$ 2.4 5.96 % $ 7 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.35 10.66 % $ 7.35 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 11.67 5.68 % $ 123 M chinaChina
Bioventus Bioventus
BVS
$ 13.22 1.85 % $ 881 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 52.37 4.21 % $ 2.79 B usaUSA
Celcuity Celcuity
CELC
$ 83.55 0.12 % $ 3.91 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.14 1.79 % $ 1.52 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 33.22 2.74 % $ 963 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 239.32 1.83 % $ 26.6 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 202.7 1.28 % $ 144 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 2.31 % $ 28.3 M israelIsrael
Fulgent Genetics Fulgent Genetics
FLGT
$ 20.56 0.54 % $ 633 M usaUSA
Guardant Health Guardant Health
GH
$ 165.87 5.39 % $ 20.8 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 169.34 0.02 % $ 13.3 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 509.72 0.99 % $ 41 B usaUSA
Illumina Illumina
ILMN
$ 207.94 0.72 % $ 32.2 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 264.81 1.16 % $ 45.5 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 314.56 0.95 % $ 26.2 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 100.27 0.02 % $ 6.77 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 591.17 0.62 % $ 17.1 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 287.94 1.01 % $ 26.5 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 3.74 9.36 % $ 346 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.68 0.98 % $ 4.47 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.27 5.51 % $ 2.34 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 11.87 0.72 % $ 2.58 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 22.14 4.83 % $ 496 M usaUSA
Natera Natera
NTRA
$ 339.13 3.1 % $ 46.4 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.55 0.38 % $ 1.16 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.36 4.23 % $ 408 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 25.15 2.28 % $ 23.8 B niderlandNiderland
Personalis Personalis
PSNL
$ 16.3 0.52 % $ 1.45 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 8.88 1.95 % $ 371 M usaUSA
Neuronetics Neuronetics
STIM
$ 2.89 5.61 % $ 191 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 611.62 0.3 % $ 231 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 136.05 6.94 % $ 8.14 B usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.31 0.34 % $ 39 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 407.54 1.67 % $ 24.3 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA